Skip to main content
Article thumbnail
Location of Repository

Intravesical Treatments of Bladder Cancer: Review

By Zancong Shen, Tong Shen, M. Guillaume Wientjes, Michael A. O’Donnell and Jessie L.-S. Au


For bladder cancer, intravesical chemo/immunotherapy is widely used as adjuvant therapies after surgical transurethal resection, while systemic therapy is typically reserved for higher stage, muscle-invading, or metastatic diseases. The goal of intravesical therapy is to eradicate existing or residual tumors through direct cytoablation or immunostimulation. The unique properties of the urinary bladder render it a fertile ground for evaluating additional novel experimental approaches to regional therapy, including iontophoresis/electrophoresis, local hyperthermia, co-administration of permeation enhancers, bioadhesive carriers, magnetic-targeted particles and gene therapy. Furthermore, due to its unique anatomical properties, the drug concentration-time profiles in various layers of bladder tissues during and after intravesical therapy can be described by mathematical models comprised of drug disposition and transport kinetic parameters. The drug delivery data, in turn, can be combined with the effective drug exposure to infer treatment efficacy and thereby assists the selection of optimal regimens. To our knowledge, intravesical therapy of bladder cancer represents the first example where computational pharmacological approach was used to design, and successfully predicted the outcome of, a randomized phase III trial (using mitomycin C). This review summarizes the pharmacological principles and the current status of intravesical therapy, and the application of computation to optimize the drug delivery to target sites and the treatment efficacy

Topics: Expert Review
Publisher: Springer US
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2003). (No authors listed). Hyaluronidase (Vitrase)–ISTA: hyaluronidase—ISTA pharmaceuticals. Drugs R&D.
  2. (1995). A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment.
  3. (2003). A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
  4. A phase I study of the safety and tolerability of intravesical administration of SCH 721015 in patients with transitional cell carcinoma of the bladder. MD Anderson cancer center.
  5. (1993). A phase II study of epirubicin in advanced transitional cell bladder cancer.
  6. (1998). A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.
  7. (2000). A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma.
  8. (1999). A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
  9. (1991). A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder.
  10. (2002). A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium.
  11. (1971). Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors.
  12. (2001). Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8.
  13. (1996). Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer.
  14. (1997). Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
  15. (1996). Alternating mitomycin-C and bacillus calmette-guerin instillation prophylaxis for recurrent papillary (stages Ta-T1) superficial bladder cancer.
  16. (1983). Aspects of the chemical stability of mitomycin and porfiromycin in acidic solution.
  17. (2003). Bacillus Calmette-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
  18. (1990). Bacillus CalmetteGuerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
  19. (1990). Bladder surface glycosaminoglycans is a human epithelial permeability barrier.
  20. (1997). Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Clin. Cancer Res.
  21. (1997). Bladder tissue pharmacokinetics of intravesical taxol.
  22. (2007). Cancer facts and figures.
  23. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res.
  24. (1999). Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.
  25. (2006). CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor—armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res.
  26. (2006). Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
  27. (1979). cis-Platinum combination chemotherapy of bladder cancer: an update. Cancer Clin. Trials.
  28. (1994). Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer.
  29. (1990). Combination chemotherapy with cis-platinum, adriamycin, mitomycinC (PAM) in patients with advanced bladder cancer.
  30. (2004). Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res.
  31. (1992). Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder.
  32. Dose-escalation study of CG0070 for bladder cancer after BCG (Bacillus Calmette-Guerin) Failure.
  33. (2003). Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin. Cancer Res.
  34. (2006). Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer.
  35. (1990). Effect of urine pH on the stability of doxorubicin and its recovery from bladder instillations.
  36. (1984). Effects of pH and temperature on the stability and decomposition of N,N’N’’-triethylenethiophosphoramide in urine and buffer. Cancer Res.
  37. (2000). Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
  38. (2006). Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
  39. (2004). Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer.
  40. (1997). Electromotive delivery of mitomycin C into human bladder wall. Cancer Res.
  41. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res.
  42. (2007). Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 codelivery.
  43. (2004). Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a 1509 Intravesical Treatments of Bladder Cancer: Reviewnonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther.
  44. (1999). Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents.
  45. (2000). Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
  46. (2006). Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
  47. (2000). Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin. Cancer Res.
  48. (1997). Hong et al. Isolation of a common receptor for coxsackie b viruses and adenoviruses 2 and 5. Science.
  49. (2005). HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res.
  50. (2006). HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res.
  51. (1977). Hyperthermic effects on DNA repair mechanisms.
  52. (2004). Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium.
  53. (1997). Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy—a phase I/II study.
  54. (2000). Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guerin as therapy for superficial bladder cancer: a comparative study.
  55. (2005). Immunotherapy for superficial bladder cancer.
  56. (2006). In vivo studies of dialkynoyl analogues of DOTAP demonstrate improved gene transfer efficiency of cationic liposomes in mouse lung.
  57. (2003). Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall.
  58. (1983). Insalaco et al. The effect of dimethyl sulfoxide on the uptake of cisplatin from the urinary bladder of the dog: a pilot study.
  59. (1992). Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer—a prospective, controlled three-armed trial. Project Group BochumInterferon and Superficial Bladder Cancer. Anti-cancer Drugs. 3(Suppl 1):33–37
  60. (1987). Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis.
  61. (2002). Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
  62. (2003). Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers.
  63. (2003). Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer. A formal meta-analysis of comparative studies on recurrence and toxicity.
  64. (1985). Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase.
  65. (1998). Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: A comparative phase II study.
  66. (2003). Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk 1506 Shen et al.superficial bladder cancer: a prospective randomized study.
  67. (2003). Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
  68. (2006). Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study.
  69. (1994). Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res.
  70. (2006). Intravesical immunotherapy:
  71. (2002). Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer—the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin. G a nT oK a g a k uR y o h o .
  72. (2002). Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer —results of a controlled prospective study.
  73. (2005). Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
  74. (2000). Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther.
  75. (2002). Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
  76. (1995). Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study.
  77. (1995). Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?—a phase II study.
  78. (2000). Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study.
  79. (1995). Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer.
  80. (2006). Kinetic model of drug distribution in the urinary bladder wall following intravesical instillation.
  81. (2006). Liposomal plasmid DNA encoding human thymosin alpha and interferon omega potently inhibits liver tumor growth in ICR mice.
  82. (2005). Low dose suramin as a chemosensitizer of bladder cancer to mitomycin
  83. (2006). Lwaleed et al. Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. Prostaglandins.
  84. (1988). M a r t i n e zT o r r e s ,R .L o p e z - P a r d o ,J .M o l i n aet al. Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1). Actas Urol.
  85. (2003). Management of Bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.
  86. (2001). Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III
  87. (1993). methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma.
  88. (1986). Mitomycin antitumor agents: a review of their physicochemical and analytical properties and stability.
  89. (1986). Mitomycin C plasma levels after intravesical instillation with and without hyaluronidase.
  90. (1995). Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study.
  91. (2000). Nonviral gene therapy: promises and challenges. Gene Ther.
  92. (2003). Nordic Urothelial Cancer Group. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study.
  93. (2001). Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer.
  94. (2000). Opportunities for the treatment of bladder cancer.
  95. (2003). Overview of the clinical efficacy of investigational anticancer drugs.
  96. (1996). Penetration of intravesical doxorubicin in human bladders.
  97. (1993). Penetration of mitomycin C in human bladder. Cancer Res.
  98. (2006). Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan.
  99. (1976). Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.
  100. (1992). Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times.
  101. (1994). Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients.
  102. (1997). Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder.
  103. (2001). Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.
  104. (2005). Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum. Gene Ther.
  105. (2005). Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
  106. (1997). Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
  107. (2006). Phase II trial of intravesical gemcitabine in Bacille Calmette-Guérin—Refractory transitional cell carcinoma of the bladder.
  108. (2006). Philopena et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther.
  109. (2000). Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.
  110. (2004). Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder.
  111. (1994). Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother.
  112. (2006). Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes. Cancer Invest.
  113. (1988). Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies.
  114. (1992). Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor
  115. (1998). Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier.
  116. (2003). Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
  117. (1974). Reproduction of poxviruses.
  118. (1998). Results of a randomised phase III trial of sequential intravesical therapy with mitomycin-C and bacillus calmette-guerin vs mitomycin-C alone in patients with superficial bladder cancer.
  119. (1992). Roest et al. Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study.
  120. (2001). Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
  121. (2005). Sato et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
  122. (1996). Semino et al. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study. Anticancer Res.
  123. (2006). Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol.
  124. (1989). Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer. Urologe A.
  125. (2006). shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity.
  126. (1994). Single instillation of hydroxypropylcellulose-doxorubicin as treatment for superficial bladder carcinoma. Cancer Chemother.
  127. (2004). SiRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.
  128. (1291). Small interfering RNAs directed against ß-Catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res.
  129. (1994). Studies on enhancement of drug absorption through the bladder mucosa. Nippon Hinyokika Gakkai Zasshi.
  130. (2002). Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
  131. (2004). Sustained intravesical drug delivery using thermosensitive hydrogel.
  132. (2005). Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens.
  133. (2001). Sutjipto et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Ther.
  134. (2002). The anti-tumor activity of bacillus CalmetteGuerin in bladder cancer is associated with an increase in the circulating level of interleukin-2.
  135. (1960). The comparative physiological disposition of thiotepa and tepa in the dog. Cancer Res.
  136. (2000). The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration.
  137. (1999). The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
  138. (1997). the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackie viruses.
  139. (2006). The role of intravesical chemotherapy in the treatment of bladder cancer.
  140. (2001). The use of valrubicin for the chemoresection of superficial bladder cancer—a marker lesion study.
  141. (2005). Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients.
  142. (1992). Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase.
  143. (1994). Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A.
  144. (1984). Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin.
  145. (1988). Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy. Urology. 31(Suppl 3):26–29
  146. (1993). Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.
  147. (2005). Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model.
  148. (2005). Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.